Group 1 - Daiichi Sankyo has appointed John Tsai, MD as the new Global Head of R&D, effective April 1, 2026, succeeding Ken Takeshita, MD [1] - Dr. Tsai brings over 25 years of experience in driving innovation and leadership in the biotech and pharmaceutical sectors, previously serving at Syncona Investment Management and Novartis AG [1] - The company aims to leverage Dr. Tsai's expertise to enhance its R&D pipeline and accelerate the development of new medicines [1] Group 2 - Daiichi Sankyo has established a new research institute in San Diego, marking its third research facility outside Japan, following locations in Boston and Munich [1] - The company emphasizes its commitment to deepening relationships in key scientific hubs to foster innovation in healthcare [1]